In this, Taiwan’s largest multi-institutional cohort study emulating the CREDENCE and DAPA-CKD trials, we investigated anemia incidence associated with initiation of SGLT2 inhibitors, focusing on patients with T2D and CKD stages 1 to 3. The gene discussed is SLC5A2; the disease is anemia (phenotype).